Anika Therapeutics, Inc.: change in inventories

What this measure means

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

Exact concept: us-gaap:IncreaseDecreaseInInventories. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2009-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.

Selected filing history

Related financial histories

• Anika Therapeutics, Inc.: total assets
• Anika Therapeutics, Inc.: stockholders equity
• Anika Therapeutics, Inc.: cash and cash equivalents
• Anika Therapeutics, Inc.: net income or loss
• Anika Therapeutics, Inc.: operating cash flow
• Anika Therapeutics, Inc.: capital expenditure payments
• Anika Therapeutics, Inc.: contract revenue excluding tax
• Anika Therapeutics, Inc.: financing cash flow
• Anika Therapeutics, Inc.: investing cash flow
• Anika Therapeutics, Inc.: retained earnings or deficit
• Anika Therapeutics, Inc.: basic weighted-average shares
• Anika Therapeutics, Inc.: diluted weighted-average shares
• Anika Therapeutics, Inc.: basic earnings per share
• Anika Therapeutics, Inc.: diluted earnings per share
• Anika Therapeutics, Inc.: income tax expense or benefit
• Anika Therapeutics, Inc.: net property, plant and equipment
• Anika Therapeutics, Inc.: share-based compensation expense
• Anika Therapeutics, Inc.: operating income or loss
• Anika Therapeutics, Inc.: current assets
• Anika Therapeutics, Inc.: current liabilities
• Anika Therapeutics, Inc.: current accounts payable
• Anika Therapeutics, Inc.: goodwill carrying amount
• Anika Therapeutics, Inc.: net current accounts receivable
• Anika Therapeutics, Inc.: common-stock repurchase payments
• Anika Therapeutics, Inc.: net inventory
• Anika Therapeutics, Inc.: gross profit
• Anika Therapeutics, Inc.: selling, general and administrative expense
• Anika Therapeutics, Inc.: research and development expense
• Anika Therapeutics, Inc.: common shares outstanding
• Anika Therapeutics, Inc.: additional paid-in capital
• Anika Therapeutics, Inc.: accumulated other comprehensive income or loss
• Anika Therapeutics, Inc.: operating lease right-of-use asset
• Anika Therapeutics, Inc.: gross property, plant and equipment
• Anika Therapeutics, Inc.: accumulated depreciation on property, plant and equipment
• Anika Therapeutics, Inc.: net intangible assets excluding goodwill
• Anika Therapeutics, Inc.: other noncurrent assets
• Anika Therapeutics, Inc.: other noncurrent liabilities
• Anika Therapeutics, Inc.: accrued current liabilities
• Anika Therapeutics, Inc.: prepaid expenses and other current assets
• Anika Therapeutics, Inc.: net deferred tax assets
• Anika Therapeutics, Inc.: net deferred tax liabilities
• Anika Therapeutics, Inc.: pre-tax income or loss from continuing operations
• Anika Therapeutics, Inc.: comprehensive income or loss
• Anika Therapeutics, Inc.: depreciation expense
• Anika Therapeutics, Inc.: depreciation, depletion and amortization
• Anika Therapeutics, Inc.: amortization of intangible assets
• Anika Therapeutics, Inc.: current income tax expense or benefit
• Anika Therapeutics, Inc.: deferred income tax expense or benefit
• Anika Therapeutics, Inc.: income taxes paid, net
• Anika Therapeutics, Inc.: change in accounts receivable
• Anika Therapeutics, Inc.: change in accounts payable

Inspect the source

Entity

Anika Therapeutics, Inc. / CIK 0000898437

Captured

2026-09-20T05:04:56.960Z

SEC response SHA-256

f1da3290842851cfa646165073c3c5bf9c06212e35bc3d1892f2be77cae8b535

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000898437.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))